Unity Recovery suspends some Philadelphia programs amid possible federal funding cuts
Unity Recovery, which has helped thousands of people rebuild their lives since 2019, has been forced to suspend much of its programming due to federal funding cuts. This includes shutting down a drop-in center in Manayunk.
In a
Facebook post shared this week
, Unity Recovery announced the severe impact of the cuts. According to the post, the federal administration's decision to retroactively slash mental health and addiction funding has led to the closure of key programs, affecting more than 700 individuals across Philadelphia and Pittsburgh. As a result, more than 20 dedicated staff members have lost their jobs, and those in need of help may no longer have access to essential recovery services.
Effective immediately, Unity Recovery has suspended several programs:
A federal court in Rhode Island on Thursday temporarily
halted the cuts
. In a
post on Facebook
, Unity Recovery said staff have "not yet received formal notification from our funders about the implications of this ruling, [but] we remain hopeful that the administration will follow the Court's orders."
"These are not just cuts. This is a dismantling of peer and community infrastructure that has been built by and for the people," executive director Robert Ashford said. "It feels hollow. It feels empty."
Ashford says the organization has an annual $2 million operating budget with 90% of funding coming from the federal government.
Since 2019, Unity Recovery has provided vital services to people like Lil.
"I cried like a baby when they said they were closed," Lil said. "People of all ages are in need."
Unity Recovery's programs have been a lifeline for people in early or long-term recovery, those experiencing homelessness, and individuals struggling with mental health.
Services range from community outreach and peer-led programs to providing essentials such as hygiene supplies and overdose prevention kits. These services are key for many individuals who have no other safety net.
In response to the crisis, Unity Recovery is calling on its community, partners and supporters to take action. They urge people to contact their elected officials, speak out on social media, and demand the restoration of funding for community-based recovery services.
"We need your voice. Your outrage. Your solidarity," Unity Recovery's post reads. "Every person impacted by substance use and mental health deserves access to care, compassion, and community. The federal government has chosen to turn its back. We ask you to stand up."
Despite the heavy blow, Ashford remains determined to continue fighting for the dignity, health and future of those they serve.
"We're bruised but not broken," he said. "We still have other funding, and we will continue to fight."
Unity Recovery's fight is far from over, and with the community's support, they hope to rebuild and continue their mission of providing hope, dignity and care for those who need it most.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
9 minutes ago
- CBS News
Phillies ace Zack Wheeler undergoes thrombolysis surgery to remove blood clot in shoulder
Phillies ace Zack Wheeler underwent thrombolysis surgery Monday morning to remove a blood clot near his right shoulder. The Phillies said Wheeler had the procedure, performed by Dr. Paul DiMuzio, at Thomas Jefferson University Hospital. The club said Wheeler's timeline to return and further treatment options are to be determined. Wheeler, 35, was placed on the 15-day injured list Saturday night with a "right upper extremity blood clot." "It could have been a much more trying situation than it is," Phillies president of baseball operations Dave Dombrowski said Saturday. Wheeler started in Washington on Friday night, allowing two runs and four hits against the Nationals. He had been dealing with right shoulder soreness for over a month. After the game, Wheeler reported feeling a "little heaviness" in his shoulder, head athletic trainer Paul Buchheit said Saturday. Buchheit said Saturday that Wheeler's blood clot was independent of his previous stiffness. "He's an ace. He's the heart of this team, the heart of this staff," Phillies reliever Matt Strahm said Monday. "You never want to see it. He's a dad. His family comes first. That's what we worry about mostly." This is a developing story and will be updated.
Yahoo
an hour ago
- Yahoo
Cancer survivors reunite, hairstylist helps detect skin cancer
In this "Dear David" installment, CBS News contributor David Begnaud highlights childhood cancer survivors Ellie Koerner and Dawson Nailor reuniting in medical school and an Arkansas hairstylist who spotted skin cancer on a client during a routine appointment. Childhood cancer survivors reunite 17 years later in medical school Two first-year medical students at the Philadelphia College of Osteopathic Medicine discovered an extraordinary connection during orientation: they had once battled the same cancer together as 4-year-olds. Ellie Koerner and Dawson Nailor were both diagnosed with acute lymphoblastic leukemia in 2007 and were treated at the Children's Hospital of Philadelphia. The two had not seen each other since their treatments ended 17 years ago. Their reunion came during a social event at orientation, when Nailor felt he recognized his new classmate. "I kept looking at her and I was like 'I know this girl from somewhere,'" Nailor said. When he approached Koerner, the moment quickly became unforgettable. Koerner recalled that Nailor tapped her on the shoulder during the event and introduced himself. As they began talking, she realized he was asking about a shared past — their time as leukemia patients. "He said, 'We were treated together.' And I was just like, speechless," Koerner said. The two immediately snapped a photo and sent it to their mothers, who remembered each other from the days their children underwent treatment. Koerner and Nailor had grown up only 10 minutes apart in South New Jersey but never crossed paths after their recoveries. "We know all the same doctors. We were treated at the exact same outpatient facility. That's how he remembered me," Koerner said. Koerner's cancer went into remission in 2008, allowing her to return to competitive gymnastics. She later captained her high school lacrosse and tennis teams. Nailor's treatment lasted longer before he underwent chemotherapy for two and a half years and went into remission. He was "cancer-free on October 1st, 2010," he said. He returned to baseball after his recovery. Even as children, both worked to support cancer patients and their families through fundraising efforts. Now, the pair stood side by side as they received their white coats — a rite of passage into the medical profession that once saved their lives. "Seventy-five percent of the reason I want to be a doctor is because I want to be the kind of doctor that treated me," Koerner said. "I feel like it's kind of been a lifelong calling in a sense to myself, you know, born out of struggle and shaped by my experiences," Nailor said. "And we've gone our separate ways in life. And now life has brought us back to going to medical school and wanting to be doctors," Koerner added. Hairstylist catches skin cancer on client's scalp, saves her life A routine hair appointment in December turned into a life-changing moment when a hairstylist noticed something unusual on her client's scalp. Cathy Burds was at Hoyt's Salon in Morrilton, Arkansas, with her service dogs, Sully and Bogart, when her cousin and stylist, Elizabeth Hoyt, spotted a concerning mark. "It's not raised like a wart… this is something altogether different," Hoyt said. Burds, a bladder cancer survivor, had already had the spot treated twice by her family practitioner, who froze it off each time. But when the mark returned, Hoyt pushed for more action. "Girl, you better listen to me, do what I said. Go to a dermatologist!" Hoyt told her client. A dermatologist later confirmed Hoyt's suspicions: the spot was skin cancer. Hoyt said her close contact with clients gives her a unique perspective to notice health changes. "You don't see your doctor but once a year. She's here about every three months. That's enough time where I could've seen a difference, and I did," Hoyt said. Burds later wrote about her experience, praising the cousin who spotted what doctors had missed. "She is one in a million, in my opinion. I am lucky she does her job. She saves lives," Burds said. After surgery in March, the cancer was successfully removed. Burds said what Elizabeth gave her will last forever. For Hoyt, watching out for her clients' health is simply part of the work. "We take care of each other but this is part of our job. It should be. I hope it is," Hoyt said. 102-year-old throws ceremonial first pitch at Cubs game A chance meeting at a Chicago airport earlier this year has catapulted a 102-year-old woman to viral fame. Beatrice Steiber told "CBS Mornings" in June that the response was overwhelming, and it didn't just stop at fan connections from all over the country. The Chicago Cubs called Steiber and invited her to throw out the ceremonial first pitch at Wrigley Field. It just proves that gratitude never gets old. David Begnaud loves uncovering the heart of every story and will continue to do so, highlighting everyday heroes and proving that there is good news in the news with his exclusive "CBS Mornings" series, "Beg-Knows America." Every Monday, get ready for moments that will make you smile or even shed a tear. Do you have a story about an ordinary person doing something extraordinary for someone else? Email David and his team at DearDavid@ Alaska Sen. Dan Sullivan on the Trump-Putin summit, sanctions and more Laufey on creating her own sound A robotics activist's remarkable crusade Solve the daily Crossword
Business of Fashion
an hour ago
- Business of Fashion
GLP-1 Pills Will Be Priced Similarly to Injections, Wall Street Predicts
US prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with their weight-loss injections, analysts and investors say, in a departure from the usual practice of charging more for new medicines despite pressure to cut prices. Neither drugmaker has disclosed pricing plans for their new daily oral medications. With regulatory approvals and launches still months away, pricing plans could change. Denmark-based Novo expects approval later this year and to launch soon after, while Indianapolis-based Lilly expects to launch by August 2026. Novo's Wegovy and Lilly's Zepbound, administered as weekly injections, are the only highly effective weight-loss drugs targeting the GLP-1 hormone, and the United States is their biggest market. US list prices are about $1,000 per month or more, with both companies offering a monthly supply for $499 to customers paying cash rather than using health insurance. Both companies have said they developed oral weight-loss drugs to meet patient needs and widen access to the market, mindful that some people are averse to injections. ADVERTISEMENT The pills, however, are not more effective than the injections. Lilly said this month its pill orforglipron cut weight by 12.4 percent after 72 weeks in a trial. That compares with weight loss of 15 percent for Novo's daily oral semaglutide. Both trail Lilly's injection at up to 21 percent. UBS analyst Trung Huynh said that will cap Lilly's pricing. The price is 'probably going to come on par with the current drugs today or slightly lower,' Huynh said. TD Cowen analyst Michael Nedelcovych said he expects Novo's pill to debut near Wegovy's price, citing the precedent of its diabetes pill Rybelsus being priced at parity with injection Ozempic, the diabetes-treatment version of Wegovy. Novo executives told analysts this month they were not in a hurry for discount pricing for the new pill. Oral GLP-1 drugs will fill a niche rather than displace injections, according to analysts. TD Cowen estimates that pills will account for a percentage share of the global obesity drug market in the mid-teens by 2030, which could reach $150 billion by then. Growing Cash Pay US doctors, patients and insurers are pressing for lower prices to make the weight-loss drugs more affordable for the 40 percent of Americans who are obese. Typically, drugmakers launch new drugs at higher prices, citing scientific advances. President Donald Trump and lawmakers from both parties have urged the companies to reduce US prices. Novo declined to comment on pricing, pointing to Aug. 6 comments by David Moore, its US operations head, saying that the company may tap customers paying cash directly via its new NovoCare pharmacy, which was launched this year to sell Wegovy outside of insurance. A Lilly spokesperson called it premature to comment on pricing and launch plans for its pill because the company has not yet submitted data for regulatory approval. Peak annual sales forecasts for Lilly's orforglipron fell to as low as $10 billion after its trial data from earlier estimates of up to $30 billion, according to a Reuters review of analyst estimates. HSBC forecasts $15 billion in peak annual sales for Novo's pill, while Barclays expects only $1 billion. ADVERTISEMENT Manufacturing Volume A key question is how much supply will be available at the time of launch. Shortages of injectable GLP-1s in 2023 and 2024 opened the US market to cheaper compounded versions as the manufacturers failed to anticipate the huge demand. 'It's all about scale and pricing,' said Kevin Gade, portfolio manager at Bahl & Gaynor, which owns Lilly shares. Gade pointed to Novo's manufacturing challenge. The pill form requires about 75 times more active ingredient than the highest-dose Wegovy injection, two analysts told Reuters. Lilly has said it already has $808.5 million in orforglipron inventory for next year's expected launch. Novo has said it will launch its pill without supply constraints after billions of dollars in investment to expand semaglutide production. Despite the high production needs, Novo is unlikely to debut its pill at a higher price than Wegovy, said Karen Andersen, healthcare strategist at Morningstar. 'Particularly in the growing cash-pay market, I doubt it can risk a launch at a premium to Wegovy,' Andersen added. By Maggie Fick and Bhanvi Satija; Editors: Caroline Humer and Will Dunham Sign up to The Business of Beauty newsletter, your complimentary, must-read source for the day's most important beauty and wellness news and analysis.
